Amanda Matter

MCPHS

Poster(s):

• (47) Payer policies and access restrictions for CRISPR-based gene therapy in sickle cell disease and beta-thalassemia: A systematic review of U.S. coverage frameworks
  Wednesday, October 29, 2025

• (49) Utilization management and coverage restrictions for gene therapies in rare pediatric diseases: a systematic review of U.S. payer policies from 2019 to 2025
  Wednesday, October 29, 2025

• (120) Coverage gaps and reimbursement barriers for FDA-authorized prescription digital therapeutics: a systematic review of U.S. health plan policies from 2018 to 2025
  Wednesday, October 29, 2025

• (200) Fragmented access to Alzheimer’s plasma biomarkers: A Medicaid policy review of coverage for early detection and anti-amyloid therapy eligibility
  Wednesday, October 29, 2025

• (310) Multicomponent interventions to improve adherence and symptom management in patients receiving CDK4/6 inhibitors: A real-world U.S. evidence review
  Wednesday, October 29, 2025

• (340) Coverage fragmentation and diagnostic access barriers in U.S. payer policies for tumor-agnostic oncology: A systematic review of NTRK-, RET-, and MSI-H–based therapies
  Wednesday, October 29, 2025